Back to mobile site

More on CGTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+54.5% Growth)
- Ratings (8.6 Score)

Upcoming Events

- Earnings (8/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Cognition Therapeutics, Inc. (NQ:CGTX)
Delayed: 1.45 +0.03 (2.11%)
Prev. Close $1.42  
Open$1.48 
52 Wk High$ 
52 Wk Low$ 
Day High$1.50 
Day Low$1.39 
P/E N/A  
EPS$ 
Volume1,303,647 

Friends, Peers and Foes (?): COCP, FBLG, PDSB, TNXP, 6XB2 (more...)

Jun 18, 2026 08:05 AM Form 8-K COGNITION THERAPEUTICS For: Jun 17
Jun 16, 2026 07:31 AM COGNITION Therapeutics receives patent notice for zervimesine to 2045
Jun 16, 2026 07:30 AM Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
Jun 4, 2026 08:01 AM Form 8-K COGNITION THERAPEUTICS For: Jun 04
Jun 1, 2026 07:30 AM Cognition Therapeutics Participating in Upcoming Investor Conferences
May 21, 2026 07:35 AM Form 8-K COGNITION THERAPEUTICS For: May 21
May 21, 2026 07:30 AM Cognition Therapeutics meets with FDA on DLB psychosis drug
May 21, 2026 07:30 AM Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 14, 2026 07:31 AM Cognition Therapeutics receives second donation to extend drug access program
May 14, 2026 07:30 AM Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
View All Articles

Entities mentioned with CGTX

View All Entities